ConductScience.org, home

Paper41246331

Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapies.

Aiello A and 22 others. Front Immunol, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapies. Papers, record 41246331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41246331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Minimal association between Th1-specific responses to COVID-19 vaccines and SARS-CoV-2 breakthrough infections in multiple sclerosis patients receiving disease-modifying therapies.
PubMed
Journal
Front Immunol
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-11-20
PubMed

Authors23

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Aiello AAlessandra
2Navarra AAssunta
3Haggiag SShalom
4Ruggieri SSerena
5Cuzzi GGilda
6Vanini VValentina
7Salmi AAndrea
8Notari SStefania
9Altera AMGAnna Maria Gerarda
10Meschi SSilvia
11Colavita FFrancesca
12Cimini EEleonora
13Tortorella CCarla
14Prosperini LLuca
15Quartuccio MEMaria Esmeralda
16Galgani SSimonetta
17Puro VVincenzo
18Maggi FFabrizio
19Grifoni AAlba
20Sette AAlessandro

Source PubMed

See all 23 authorsDownload CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
COVID-19Major topic
Th1 CellsMajor topic
Multiple SclerosisMajor topic
SARS-CoV-2Major topic
COVID-19 VaccinesMajor topic
Humans
Female
Male
Middle Aged
Adult
Cytokines
Prospective Studies
Immunosuppressive Agents
Spike Glycoprotein, Coronavirus
Fingolimod Hydrochloride
Breakthrough Infections

Source PubMed

Download CSV of topics

References78

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136367013Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022.Euro Surveill2022https://conductscience.org/library/papers/36367013PubMed
234274038Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.Lancet2021https://conductscience.org/library/papers/34274038PubMed
334522051Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.Nat Med2021https://conductscience.org/library/papers/34522051PubMed
435526306Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.EBioMedicine2022https://conductscience.org/library/papers/35526306PubMed
522987802Macrophages induce differentiation of plasma cells through CXCL10/IP-10.J Exp Med2012https://conductscience.org/library/papers/22987802PubMed
638896777Variant-specific antibody response following repeated SARS-CoV-2 vaccination and infection.Cell Rep2024https://conductscience.org/library/papers/38896777PubMed
740086617Diagnostic tests for tuberculosis infection and predictive indicators of disease progression: Utilizing host and pathogen biomarkers to enhance the tuberculosis elimination strategies.Int J Infect Dis2025https://conductscience.org/library/papers/40086617PubMed
835305296Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.Lancet2022https://conductscience.org/library/papers/35305296PubMed
936628884Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.Mult Scler Relat Disord2023https://conductscience.org/library/papers/36628884PubMed
1040137720Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs.Pathogens2025https://conductscience.org/library/papers/40137720PubMed
1136037755Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies.Mult Scler Relat Disord2022https://conductscience.org/library/papers/36037755PubMed
1235632451COVID-19 Vaccination in Multiple Sclerosis and Inflammatory Diseases: Effects from Disease-Modifying Therapy, Long-Term Seroprevalence and Breakthrough Infections.Vaccines (Basel)2022https://conductscience.org/library/papers/35632451PubMed
1334648302mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.Science2021https://conductscience.org/library/papers/34648302PubMed
1436522154Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies.J Neurol Neurosurg Psychiatry2023https://conductscience.org/library/papers/36522154PubMed
1536999398Peri-infection titers of neutralizing and binding antibodies as a predictor of COVID-19 breakthrough infections in vaccinated healthcare professionals: importance of the timing.Clin Chem Lab Med2023https://conductscience.org/library/papers/36999398PubMed
1638932415SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma.Vaccines (Basel)2024https://conductscience.org/library/papers/38932415PubMed
1739204049Anti-RBD Antibody Levels and IFN-γ-Specific T Cell Response Are Associated with a More Rapid Swab Reversion in Patients with Multiple Sclerosis after the Booster Dose of COVID-19 Vaccination.Vaccines (Basel)2024https://conductscience.org/library/papers/39204049PubMed
1835235002Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.J Neurol2022https://conductscience.org/library/papers/35235002PubMed
1939612915Interleukin-2-secreting T helper cells promote extra-follicular B cell maturation via intrinsic regulation of a B cell mTOR-AKT-Blimp-1 axis.Immunity2024https://conductscience.org/library/papers/39612915PubMed
2024655300Chemokines and chemokine receptors: positioning cells for host defense and immunity.Annu Rev Immunol2014https://conductscience.org/library/papers/24655300PubMed

See all 78 referencesDownload CSV of references

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CXCL103627PubTator's text mininghttps://conductscience.org/library/genes/3627NCBI Gene
IFNB13456PubTator's text mininghttps://conductscience.org/library/genes/3456NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41246331

GET https://conductscience.org/api/papers/v1/41246331/authors?page=2